stockrow
Friday 6 November 2026
Export APUS’s income statement to Excel — free account
Apimeds Pharmaceuticals US, Inc.
APUS Healthcare Drug Manufacturers Specialty & Generic
- EPS
- −352.7%
- Free cash flow
- −67.9%
- Total debt
- +2,468.3%
Quarter to June 2026, against a year earlier
2.62
0.11
−4.03%
Follow APUS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | (1) | (1) | (6) | (58) | +177.8% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | (1) | (1) | (6) | (58) | +177.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (1.69) | (1.80) | (5.50) | (36.68) | +80.3% | ||||||
| Cash flow | — | — | — | — | — | — | — | (1.37) | (0.93) | (8.20) | (7.75) | +145.1% | ||||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | (0.05) | (0.03) | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | (1.37) | (0.93) | (8.25) | (7.78) | +145.9% | ||||||
| Book value | — | — | — | — | — | — | — | 0.07 | (1.72) | 140.92 | 62.14 | +4,406.1% | ||||||
| Shares, m | — | — | — | — | — | — | — | 0 | 1 | 1 | 1 | +53.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (1) | (9) | (13) | +277.1% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (1) | (9) | (13) | +278.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 0 | (1) | 3 | (10) | +231.2% | |||||
| Net debt | — | — | — | — | — | — | — | 0 | 0 | (5) | 1 | +462.6% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 0 | (1) | 153 | 106 | +6,833.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (638.79) | (7.31) | (84.20) | (7.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | (5.00) | (15.96) | (5.0) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 209.62 | (7.90) | (100.13) | (7.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 2 | 2 | 7 | — | +87.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
Apimeds Pharmaceuticals US, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| UPC Universe Pharmaceuticals INC | $7.0M | — (loss-making) | 4.1× | −23.98% (below 0%: shrinking) | −110.15% (below 0%: shrinking) | −84.99% (below 0%: shrinking) | 32.57% | 0.00% | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.1M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.9M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| YCBD cbdMD, Inc. | $4.4M | — (loss-making) | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| Median of peers | $4.1M | — | — | +20.55% | — | −2.68% | 32.57% | 0.00% |